Personalized Cancer Care. Realized.

Forging a Clearer Path to Cancer Treatments

Allarity Therapeutics CEO Letter to ShareholdersRead the letter from CEO James G. Cullem  to Allarity’s shareholders and other stakeholders, published on August 11, 2023

Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.

Our Pipeline

Allarity’s robust pipeline includes five anti-cancer drugs that address significant cancer markets. All programs include a DRP® companion diagnostic to select patients most likely to respond to treatment.

Our Platform

Our DRP® Technology is a first-in-class, highly validated diagnostic platform that models human tumor biology and can help predict whether a cancer patient will respond or not to a particular drug


Results from our DRP® platform have been published in numerous peer-reviewed scientific journals, highlighting the predictive capabilities of our proprietary approach to precision medicine.




The DRP® Platform

No two people are the same. Neither are their cancers. DRP® technology is a unique and best-in-class proprietary diagnostic platform built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types, and refined with actual gene expression data from more than 3,000 patient tumors
Play Video

"We are building a personalized medicine company developing new therapeutics for unmet needs in the treatment of human cancers through use of our world-class companion diagnostics platform."

James G. Cullem, CEO

Allarity Leadership James Cullem